<DOC>
	<DOCNO>NCT01285414</DOCNO>
	<brief_summary>This , international , multi-center , Phase 2 study verubulin conduct patient newly diagnose Glioblastoma Multiforme ( GBM ) . The study conduct two part . Part A open-label dose find study determine safety tolerability verubulin combination standard treatment . Part B randomize open-label study investigate progression-free survival overall survival patient receive verubulin , dose determine Part A , combination standard treatment versus standard treatment alone .</brief_summary>
	<brief_title>Verubulin , Radiation Therapy , Temozolomide Treat Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Have histologically prove , newly diagnose glioblastoma multiforme 2 . Age ≥ 18 year &lt; 70 year 3 . Have ECOG performance score 0 , 1 , 2 , KPS ≥ 70 4 . Have adequate bone marrow function , liver function , kidney function start therapy 5 . Begin study therapy 6 week surgery biopsy 6 . Subjects surgery must MRI ≤ 72 hour surgery 1 . Have carmustine implant ( e.g. , Gliadel® Wafer ) 2 . Have uncontrolled hypertension ( SBP &gt; 140 mmHg DBP &gt; 90 mmHg 1 week ) 3 . Have leave ventricular ejection fraction lower limit reference range institution , measure multiple gated acquisition ( MUGA ) echocardiogram ( ECHO ) 4 . Have TroponinI Troponin T Screening visit elevate upper limit reference range local institution 5 . Have increase steroid requirement , indicative rapidly progressive disease 6 . Have evidence new , active intra tumor hemorrhage ≥ CTCAE Grade 2 7 . Have prior cranial radiotherapy 8 . Have history stroke and/or transient ischemic attack within 2 year screen 9 . Have history cardiovascular disease ( e.g. , angina , myocardial infarction , congestive heart failure , etc . ) within 2 year screen 10 . Be pregnant breast feed 11 . Have history hypersensitivity reaction Cremophor® EL 12 . Have history hypersensitivity reaction intolerance temozolomide dacarbazine ( DTIC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Brain Neoplasms</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Verubulin</keyword>
</DOC>